Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE CONSEIL PASSY : revenue, balance sheet and financial ratios

PHARMACIE CONSEIL PASSY is a French company founded 21 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75016), this company of category PME shows in 2023 a net income positive of 311 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE CONSEIL PASSY (SIREN 481280287)
Indicator 2023 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C N/C N/C
Net income 311 446 € 547 025 € 58 211 € -22 385 € 80 877 € 38 113 €
EBITDA N/C N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2023, PHARMACIE CONSEIL PASSY generates positive net income of 311 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2023: 38 k€ -> 311 k€.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

311 446 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 183%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 30%. The balance between equity and debt is satisfactory.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

183.096%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

29.711%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

56.4%

Solvency indicators evolution
PHARMACIE CONSEIL PASSY

Sector positioning

Debt ratio
183.1 2023
2020
2021
2023
Q1: 20.09
Med: 66.92
Q3: 169.22
Average

In 2023, the debt ratio of PHARMACIE CONSEIL PASSY (183.10) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
29.71% 2023
2020
2021
2023
Q1: 28.71%
Med: 48.51%
Q3: 68.18%
Average

In 2023, the financial autonomy of PHARMACIE CONSEIL PASSY (29.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 257.61. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

257.614

Liquidity indicators evolution
PHARMACIE CONSEIL PASSY

Sector positioning

Liquidity ratio
257.61 2023
2020
2021
2023
Q1: 135.26
Med: 189.75
Q3: 270.27
Good

In 2023, the liquidity ratio of PHARMACIE CONSEIL PASSY (257.61) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE CONSEIL PASSY

Positioning of PHARMACIE CONSEIL PASSY in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2023, the value of PHARMACIE CONSEIL PASSY is estimated at 3 674 899 € (range 2 234 882€ - 5 166 084€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
220 transactions
2234k€ 3674k€ 5166k€
3 674 899 € Range: 2 234 882€ - 5 166 084€
NAF 5 année 2023

Valuation method used

Net Income Multiple
311 446 € × 11.8x = 3 674 900 €
Range: 2 234 882€ - 5 166 084€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE CONSEIL PASSY with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE CONSEIL PASSY

What is the revenue of PHARMACIE CONSEIL PASSY ?

The revenue of PHARMACIE CONSEIL PASSY is not publicly disclosed (confidential accounts filed with INPI).

Is PHARMACIE CONSEIL PASSY profitable?

Yes, PHARMACIE CONSEIL PASSY generated a net profit of 311 k€ in 2023.

Where is the headquarters of PHARMACIE CONSEIL PASSY ?

The headquarters of PHARMACIE CONSEIL PASSY is located in PARIS (75016), in the department Paris.

Where to find the tax return of PHARMACIE CONSEIL PASSY ?

The tax return of PHARMACIE CONSEIL PASSY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE CONSEIL PASSY operate?

PHARMACIE CONSEIL PASSY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.